Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Infinium Pharmachem Pvt Ltd

    Infinium Pharmachem Pvt Ltd incorporated in 2003, is a Gujarat-based company engaged in the manufacture of iodine derivatives and allied products. The company is promoted by Mr.

  • No Image
    Infutec Healthcare Ltd

    Infutec Healthcare Ltd (100% Wholly Owned Subsidiary of Parenteral Drugs India Ltd.) are manufacturing FFS IV Fluids in 100ml., 350ml., 400ml., 500ml. & 1000ml. The company has

  • No Image
    Intas Pharmaceuticals Ltd

    Intas is one of the fastest growing Indian pharmaceutical majors. Its focus is on super-specialty in Central Nervous System (CNS), Nephrology, Gastroenterology, Urology, Orthopa

  • No Image
    Integral Biosciences Pvt Ltd

    Integral Biosciences Pvt Ltd is a Noida-based (Uttar Pradesh) contractual research organization (CRO) established with the aim of providing medicinal chemistry research services